April 16, 2015
Weil’s Washington, D.C. Antitrust practice was recognized as “Outstanding” by Global Competition Review (GCR) in its recent survey of the antitrust bar in the nation’s capital. The practice was ranked in a select category for antitrust teams based on its size, client base and sophistication. The survey included a total of 43 firms, the largest bar survey ever conducted by GCR.
Weil was noted for its “deep bench” and its unmatched ability to handle “tricky pharmaceutical deals.” Global Antitrust/Competition practice head Steven Newborn was praised along with Ann Malester, Steven Bernstein, Jim Egan and Jeff Perry.
GCR, referring to Weil as a “surging M&A engine,” highlighted some of the Antitrust practice’s recent work for such clients as AbbVie, Johnson & Johnson and Actavis. Since acting for Forest Laboratories in Actavis’ 2014 takeover of the company, Weil’s Antitrust team has advised Actavis on other major deals as well – one involving AstraZeneca and another involving the $66 billion purchase of Botox-maker Allergan.
On the litigation side, partner Carrie Anderson and the Weil team have advised Hilton, Actavis and Michael Foods and recently secured a $58.5 million settlement on behalf of a class of television stations against performing rights organization SESAC.
GCR is a resource for over 10,000 competition professionals worldwide and is recognized as the world’s leading competition law and policy journal and news service.